Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | NNMT | P40261 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5699279 | 0.79 | KMT2A (0.57) | MEN1KMT2AGPR84L3MBTL1ABL1 | |
| SCHEMBL128526 | 0.79 | MEN1 (0.68) | MEN1KMT2AGPR84L3MBTL1ABL1 | |
| SCHEMBL29618255 | 0.79 | MEN1 (0.68) | MEN1KMT2AGPR84L3MBTL1ABL1 | |
| SCHEMBL14198090 | 0.78 | MEN1 (0.55) | MEN1KMT2AGPR84L3MBTL1ABL1 | |
| SCHEMBL1447053 | 0.76 | MEN1 (0.53) | MEN1KMT2AGPR84L3MBTL1ABL1 | |
| SCHEMBL1447051 | 0.76 | MEN1 (0.53) | MEN1KMT2AGPR84L3MBTL1ABL1 | |
| SCHEMBL29618133 | 0.72 | MEN1 (0.64) | MEN1KMT2AGPR84L3MBTL1ABL1 | |
| Oxiniacic Acid SCHEMBL129209 | 0.72 | MEN1 (1.00) | MEN1KMT2AGPR84L3MBTL1ABL1 | |
| Oxiniacic Acid SCHEMBL29766756 | 0.72 | MEN1 (1.00) | MEN1KMT2AGPR84L3MBTL1ABL1 | |
| SCHEMBL4120256 | 0.72 | MEN1 (0.58) | MEN1KMT2AGPR84L3MBTL1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024306-A1 | PROCESSES FOR PREPARING ARIMOCLOMOL CITRATE AND INTERMEDIATES THEREOF | ZEVRA DENMARK AS (DK) | 2024-01-25 | — | — | US | disclosed |
| US-11707456-B2 | Processes for preparing arimoclomol citrate and intermediates thereof | KEMPHARM DENMARK A/S | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707456-B2 | Processes for preparing arimoclomol citrate and intermediates thereof | ACLY, AURKC, AURKA | MEN1 4132/4885KMT2A 1948/4885GPR84 1944/4885 |
| US-20240024306-A1 | PROCESSES FOR PREPARING ARIMOCLOMOL CITRATE AND INTERMEDIATES THEREOF | ACLY, AURKC, AURKA | MEN1 4132/4885KMT2A 1948/4885GPR84 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.